Increased percentage of B cells in patients with more advanced hepatocellular carcinoma

Lin, Jiunn Chang; Shih, Yu‐Lueng; Chien, Pei Ju; Liu, Chien‐Liang; Lee, Jie Jen; Liu, Tsan Pai; Ko, Wen Ching; Shih, Chwen Ming

doi:10.1016/j.humimm.2009.10.003

Cited by 11 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower percentages of B and T helper lymphocytes in the peripheral blood of HCC patients suggest defective adaptive immunity. 14 Interestingly, in the present study, the simultaneously and significantly decreased total and activated T and B cells were only observed in 9 M Ras-Tg with multiple massive hepatic tumors, but not in 3 M and 5 M Ras-Tg with a few hepatic lesions ( Figs. 1-3).…”

Section: Discussioncontrasting

confidence: 47%

“…Namely, a greater B cell proportion and a higher IgG2 concentration resulted in a lower incidence of nodules <2 mm diameters in homozygous in contrast to heterozygous males. In addition, the increased B cell proportion and IgG2 levels in homozygotes may result from the evoked adaptive immunity in response to the large tumor burdens …”

Section: Resultsmentioning

confidence: 99%

“…In addition, the increased B cell proportion and IgG2 levels in homozygotes may result from the evoked adaptive immunity in response to the large tumor burdens. 14…”

Section: B Cell Proportion and Igg2 Concentrations Negatively Correlamentioning

confidence: 99%

See 2 more Smart Citations

B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice

et al. 2017

View full text Add to dashboard Cite

Increasing reports show noninflammation underlying HCC, challenging our understanding of the roles of the immune system in hepatocarcinogenesis. By exploring a mouse model of hepatic tumor induced by hepatocyte-specific expression of the Hras12V oncogene without obvious inflammation, we found that the proportion of B cells, but not T cells, progressively and significantly decreased in 3, 5-month-old transgenic mice (Tg) compared with non-transgenic mice. Notably, the proportions of total and activated B and T cells all significantly decreased in 9-month-old Tg with multiple massive hepatic tumors. Together with the decreased B cell proportion, serum IgG1/2 also significantly decreased in 5, 9-month-old Tg. Interestingly, homozygous Tg showed significantly higher B cell proportion and IgG2 levels, accompanied by significantly lower incidences of liver nodules but not adenomas and carcinomas compared with heterozygous Tg. Treatment of Tg with PCI-32765, a potent Bruton's tyrosine kinase (BTK) inhibitor for suppressing B cell proliferation and activation, significantly decreased the B cell proportion and IgG2 levels, accompanied by a significantly higher incidence of liver nodules, but had no effects on adenoma and carcinoma. Treatment of Tg with insulin-like growth factor 1 (IGF-1) significantly increased the B cell proportion and IgG2 levels, accompanied by a significantly lower incidence of liver nodules and carcinoma, but had no effects on adenoma. Conclusively, B cells and IgG2 may play important roles in suppressing hepatic tumorigenesis, but not development. In addition, hepatocyte-specific expression of the ras oncogene may play roles in suppressing B cells, while developed hepatic tumors suppress both B and T cells.

show abstract

Section: Discussioncontrasting

confidence: 47%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Moreover, an increased percentage of CD19 + CD24 + CD38 + Bregs in HCC patients has also been found to correlate with advanced tumor staging compared to patients with early stages of HCC and healthy controls. 106 CD19 + CD24 + CD38 + Bregs in HCC patients have been shown to promote HCC cell growth through direct interactions with hepatic cancer cells via the CD40/CD154 signaling pathway, thus supporting a role for Bregs in cancer progression. 107 Furthermore, glioma cell-derived placental growth factor has been shown to promote the proliferation of intratumoral B cells by inducing their differentiation from naive B cells into TGF-β + Bregs that suppress CD8 + responses.…”

Section: Regulatory B-cell Subsets In Cancermentioning

confidence: 88%

B cell regulation in cancer and anti-tumor immunity

2017

View full text Add to dashboard Cite

The balance between immune effector cells and immunosuppressive cells and how this regulates the tumor microenvironment has been well described. A significant contribution of immune regulatory cells, including regulatory T cells, to tumor progression has been widely reported. An emerging body of evidence has recently recognized a role for B cells in modulating the immune response to tumors and lymphoid malignancies. Regulatory B cells (Bregs) are a newly designated subset of B cells that have been shown to play a pivotal role in regulating immune responses involved in inflammation, autoimmunity and, more recently, cancer. Bregs can suppress diverse cell subtypes, including T cells, through the secretion of anti-inflammatory mediators, such as IL-10, and can facilitate the conversion of T cells to regulatory T cells, thus attenuating anti-tumor immune responses. Similar B-cell subpopulations have been reported to be recruited to the tumor but to acquire their immunosuppressive properties within the tumor bed and thereby attenuate anti-tumor immune responses. However, despite a pivotal role for Bregs in promoting inflammation and carcinogenesis, the phenotypic diversity of the cell surface markers that are unique to Bregs remains unclear in mice and humans. In this review, we summarize the characteristics of Bregs and review our current knowledge of Bregs and their inhibition of anti-tumor immune responses in murine tumor models and cancer patients.

show abstract

“…Recent evidence has suggested that B cells exhibit dual biological effects in promoting and inhibiting the development and progression of several cancers [8] . Regarding HCC, a previous study showed that increased percentage of circulating B cells was found in individuals with advanced HCC compared with early tumor staging [9] . Recently, it was also demonstrated that tumor infiltrating B cells was associated with disease prognosis in patients with HBV-related HCC [10] .…”

Section: Introductionmentioning

confidence: 99%

Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma

Khlaiphuengsin¹,

Chuaypen²,

Sodsai³

et al. 2020

WJG

View full text Add to dashboard Cite

BACKGROUND Recent evidence has indicated the role of B cells and B cell-activating factor (BAFF) in the development of hepatocellular carcinoma (HCC). AIM To characterize circulating BAFF receptor expression and B cell subpopulations in patients with hepatitis B virus (HBV)-related HCC. METHODS Peripheral blood samples collected from 41 patients with chronic HBV infection (25 patients without HCC and 16 patients with HCC) and 9 healthy controls were assessed for BAFF receptors [BAFF-R(B cell-activating factor receptor), transmembrane activator and cyclophilin ligand interactor, B-cell maturation antigen] and B cell subpopulations by multicolor flow cytometry.

show abstract

Increased percentage of B cells in patients with more advanced hepatocellular carcinoma

Cited by 11 publications

References 43 publications

B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice

B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice

B cell regulation in cancer and anti-tumor immunity

Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma

Contact Info

Product

Resources

About